Medications

AstraZeneca suffers diabetes drug setback for COVID

British pharmaceutical giant AstraZeneca on Monday said that following a trial, its diabetes drug Farxiga was not successful in treating COVID patients at risk of severe complications.

Vaccination

AstraZeneca suspension did not impact vaccine intentions

New research from the University of Stirling has shown that the suspension of the AstraZeneca COVID-19 vaccination had no effect on the UK general public's intention of getting the vaccination.

Vaccination

AstraZeneca US trials thrown into doubt after promising data

A US health agency raised concerns Tuesday that AstraZeneca may have included out-of-date information during trials of its COVID-19 vaccine, a day after the company said its drug was highly effective in preventing the disease.

Vaccination

France recommends AstraZeneca jab for over-55s only

France's health regulator recommended Friday that only people aged 55 and over be administered AstraZeneca's COVID-19 vaccine due to reports of blood clots, while giving the green light to resume its use after a brief suspension.

Vaccination

Europe pause of AstraZeneca sends ripple of doubt elsewhere

The suspension of the AstraZeneca vaccine in several European countries over the past week could fuel skepticism about the shot far beyond their shores, potentially threatening the rollout of a vaccine that is key to the ...

page 4 from 7